AVA™ Emulation System
AVA™ Emulation System A high-throughput Organ-Chip platform that generates human-relevant data at scale
Receive your quote directly from the manufacturer.
AVA is a self-contained 3-in-1 Organ-Chip platform that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run, delivering in vivo fidelity at scale. AVA is compatible with Chip-Array Organ-Chip consumables, which enable users to create 12 independent Organ-Chip samples per Chip-Array.
Applications:
Cell Models, Cell Culture, 3D Cell Models, Drug Discovery & Development, Organoid Research, Toxicology, cell & gene therapy, cancer, immunology, neuroscience, infectious disease, Organ-on-a-Chip technology.
Media Flow: 15–2,000 µL / h. Different flow rates can be set for top versus bottom microfluidic channels, including no flow if desired.
Capacity: Up to 8 Chip-Arrays for a total of 96 Organ-Chip Emulations per run
Air-Liquid Interface: Yes
Size: 762 x 445 x 559 mm
Weight: 63.5kg
Gas Input: 100% CO2
Relative Humidity: 80-95%
Operating Temperature: 37ºC
Predicting patient-specific therapeutic responses with organ-on-a-chip technology
This session brings together Dr. Lorenzo Ferri of McGill University and Dr. Donald Ingber of Harvard’s Wyss Institute to showcase a breakthrough in personalized cancer care. Dr. Ferri highlights the challenge of treating esophageal cancer, where traditional chemotherapy often fails and patients endure toxicity without guaranteed benefit. His team now combines patient‑derived organoids with Dr. Ingber’s organ‑on‑a‑chip technology to recreate each patient’s tumor in a dynamic, lifelike environment.
These cancer‑on‑chips accurately predict how an individual will respond to chemotherapy, something organoids alone can’t fully achieve. The platform even reveals how stromal and immune cells shape treatment resistance. Using high‑throughput drug screens, the team identifies existing drugs that can “rescue” chemo‑resistant tumors, converting them into treatment‑responsive ones on the chip.
Organ-on-chip benchtop system for fast and reliable human-relevant data
Looking for a faster, more reliable way to generate human-relevant preclinical data? In this SelectScience interview, Lorna Ewart, CSO at Emulate, presents the AVA™ Emulation System, the first benchtop organ-on-chip platform combining automated microfluidics with high-resolution imaging. Discover how the AVA™ Emulation System enhances lab efficiency, enables streamlined downstream analysis, supports regulatory compliance, and drives the move toward more predictive, ethical, non-animal models in preclinical research.
This video was filmed at SLAS 2026, where Emulate's AVA™ Emulation System won a 2026 SLAS New Product Award.
Human‑relevant drug testing reaches new throughput milestone
How Emulate's 96-chip AVA™ Emulation System is helping pharmaceutical companies transition to human-relevant testing under new FDA and UK regulatory guidelines
